Loss prevention case of the month. Monitoring remains critical.
D000082:Acetaminophen / Q000627:therapeutic use; D000380:Agranulocytosis / Q000209:etiology; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D018501:Antirheumatic Agents / Q000009:adverse effects*; D002983:Clinical Competence; D003951:Diagnostic Errors; D004316:Doxepin / Q000627:therapeutic use; D016903:Drug Monitoring; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D006853:Hydrocodone / Q000627:therapeutic use; D007052:Ibuprofen / Q000627:therapeutic use; D007213:Indomethacin / Q000627:therapeutic use; D008875:Middle Aged; D012460:Sulfasalazine / Q000009:adverse effects*; D013997:Time Factors; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000627:therapeutic use
D000894:Anti-Inflammatory Agents, Non-Steroidal; D018501:Antirheumatic Agents; D004316:Doxepin; D000082:Acetaminophen; D012460:Sulfasalazine; D006853:Hydrocodone; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D007052:Ibuprofen; D007213:Indomethacin